Hormone replacement in women with a history of breast cancer

Oncologist

Volumn 6, Issue 4, 2001, Pages 353-362

  Pritchard, Kathleen I ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Breast cancer; Estrogen; Hormone replacement therapy; Progesterone

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BELLERGAL; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CLONIDINE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; MEDROXYPROGESTERONE; MEGESTROL ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PROGESTERONE; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; VENLAFAXINE;

ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COLON CANCER; DIET; ESTROGEN DEFICIENCY; EXERCISE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; PROGESTERONE;

EID: 0034868662     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-4-353     Document Type: Article

References (89)

1. Measuring the impact of menopausal symptoms in quality of life
2. The prevention and treatment of osteoporosis
3. Menopause and the risk of coronary heart disease in women
4. Oral medroxyprogesterone in the treatment of postmenopausal symptoms
5. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women
6. Estrogen replacement therapy and fractures in older women
7. Treatment of postmenopausal osteoporosis with transdermal estrogen
8. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women
9. Effects of pharmacologic agents used during menopause: Impact on lipids and lipoproteins
10. Sex steroid hormone receptors in the cardiovascular system
11. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
12. Postmenopausal hormone therapy and mortality
13. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
14. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
15. Design of the Women's Health Initiative clinical trial and observational study
16. Estrogen deficiency and risk of Alzheimer's disease in women
17. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. A randomized controlled trial
18. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
19. Management of menopausal symptoms in breast cancer survivors
20. Alternatives to estrogen for menopausal women
21. Making informed choices about menopause
22. Double-blind crossover trial of Replens versus KY Jelly for treating vaginal dryness and dyspareunia in breast cancer survivors
23. A one year multicenter study of efficacy and safety of a continuous, low dose estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging
24. Estrogen therapy during menopause. Practical treatment recommendations
25. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes
26. Megestrol acetate for the prevention of hot flashes
27. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors
28. Pilot evaluation of Venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
29. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial
30. Long term use of megestrol acetate for treatment of hot flashes in cancer survivors
31. Effect of oral Alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis
32. Chemical castration induced by adjuvant cyclophosphamide, methotrexate and flurouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients
33. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind placebo-controlled study
34. Reduction of skeletal morbidity and prevention of bone metastases with oral clodronate in women with recurrent breast cancer in the absence of skeletal metastases
35. Efficacy of Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
36. Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases
37. Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women
38. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
39. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
40. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
41. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial
42. Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter, double-blind, randomized trials in ∼12,000 post-menopausal women
43. Calcium and osteoporosis
44. Physical activity as therapy for osteoporosis
45. Non-pharmacological modification of cardiac risk factors
46. Cholesterol lowering with statin drugs, risks of stroke, and total mortality
47. Statins do more than just lower cholesterol
48. NSAID use and decreased risk of gastrointestinal cancers
49. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
50. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems
51. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users
52. Postmenopausal estrogens - Opposed, unopposed, or none of the above
53. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone
54. Risks of breast and endometrial cancer after estrogen and progestin replacement
55. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
56. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
57. Prospective study of exogenous hormones and risk of pulmonary embolism in women
58. Risk of venous thromboembolism in users of hormone replacement therapy
59. Venous thromboembolic events associated with hormone replacement therapy
60. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography
61. Pain and increased mammographic density in women receiving hormone replacement therapy: A prospective study
62. Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids
63. Ovarian ablation in early breast cancer: An overview of the randomized trials
64. Estrogen replacement therapy in women with breast cancer: A survey of patient attitudes
65. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy
66. Breast cancer and pregnancy: The ultimate challenge
67. Hormone replacement after breast cancer
68. A randomized pilot study of HRT in breast cancer patients: The combined effects of tamoxifen and HRT on the endometrium
69. Hormone replacement therapy in previously treated breast cancer patients
70. A case controlled study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer
71. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer
72. Breast cancer response to hormone replacement therapy withdrawal
73. Estrogen withdrawal as initial treatment for metastatic breast cancer
74. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy
75. Prognostic characteristics in breast cancers after hormone replacement therapy
76. Hormone replacement therapy and high S phase in breast cancer
77. Decision analysis (DA) of estrogen replacement therapy (ERT) in women made prematurely menopausal during adjuvant chemotherapy (ADJ/CXT) for breast cancer (BC)
78. Projections of the longevity effects of tamoxifen (TAM) + progestin (T+P) versus hormone replacement therapy (HRT) in breast cancer survivors requiring hormonal symptom relief
79. Eliciting preferences for adjuvant therapy in patients with early stage breast cancer: Tradeoffs between treatment, care, and survival
80. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial
81. The use of a probability trade-off task (PT-OT) to assess maximal acceptable increment in risk of breast cancer recurrence (MAIRR) in order to estimate sample size for a randomized clinical trial of hormone replacement therapy (HRT) in women with a previous diagnosis of breast cancer
82. Randomized prospective trial of estrogen replacement therapy in women with a history of breast cancer
83. Elements of informed consent for hormonal replacement therapy in patients with diagnosed breast cancer
84. Hormone replacement therapy in women treated for breast cancer
85. Hormone replacement therapy in breast cancer survivors: A cohort study
86. Hormone replacement therapy (HRT) in breast cancer survivors
87. Hormone replacement therapy (HRT) in women with previously treated primary breast cancer, update IV
88. Traitment hormonal substitutif de menopause chez la femme ayant des antecedents personnels de mastopathie benigne on de cancer du sein
89. Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed propectively